Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 2/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533006 | 0.86 | GRK2 (0.64) | GRK2EPHX2MAPK8MAPK10MAPK13 | |
| SCHEMBL14496328 | 0.79 | GRK2 (1.00) | GRK2 | |
| SCHEMBL12514132 | 0.71 | EPHX2 (0.73) | GRK2EPHX2CYP2C9CYP2C19POLB | |
| SCHEMBL14496412 | 0.71 | GRK2 (1.00) | GRK2EPHX2 | |
| SCHEMBL5539702 | 0.71 | GRK2 (0.59) | GRK2 | |
| SCHEMBL9312796 | 0.68 | CYP2C19 (0.70) | EPHX2CYP2C9CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL9312802 | 0.68 | CYP2C19 (0.71) | EPHX2CYP2C9CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL2720343 | 0.67 | CYP2C19 (0.69) | EPHX2CYP2C9CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL279958 | 0.67 | CYP2C19 (0.72) | EPHX2CYP2C9CYP2C19POLBSMN1; SMN2 | |
| SCHEMBL29584690 | 0.67 | CYP2C19 (0.69) | EPHX2CYP2C9CYP2C19POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | GRK2 2/4885EPHX2 2838/4885MAPK8 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.